Fulcrum Therapeutics, Inc. (FULC)
9.51
-0.34
(-3.45%)
USD |
NASDAQ |
Jan 12, 16:00
9.52
+0.01
(+0.11%)
After-Hours: 20:00
Fulcrum Therapeutics Research and Development Expense (Annual): 61.79M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Agios Pharmaceuticals, Inc. | 295.63M |
| Biogen, Inc. | 1.755B |
| CorMedix, Inc. | 3.942M |
| Apellis Pharmaceuticals, Inc. | 327.57M |
| NovaBay Pharmaceuticals, Inc. | 0.042M |